Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-03-06
2007-03-06
O'Hara, Eileen (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S389100, C530S387100
Reexamination Certificate
active
10324493
ABSTRACT:
Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 antagonist to a patient afflicted with such a condition. Suitable IL-4 antagonists include, but are not limited to, IL-4 receptors (such as a soluble human IL-4 receptor), antibodies that bind IL-4, antibodies that bind IL-4R, IL-4 muteins that bind to IL-4R but do not induce a biological response, molecules that inhibit IL-4-induced signal transduction, and other compounds that inhibit a biological effect that results from the binding of IL-4 to a cell surface IL-4R. Particular antibodies provided herein include human monoclonal antibodies generated by procedures involving immunization of transgenic mice. Such human antibodies may be raised against human IL-4 receptor. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities.
REFERENCES:
patent: 5717072 (1998-02-01), Mosley et al.
patent: 6716587 (2004-04-01), Mosley et al.
patent: 0 604 693 (1994-07-01), None
patent: WO 90/05183 (1990-05-01), None
patent: WO 91/09059 (1991-06-01), None
patent: WO 94 21282 (1994-09-01), None
patent: WO 96/33735 (1996-10-01), None
patent: WO 96/34096 (1996-10-01), None
patent: WO 00/18932 (2000-04-01), None
patent: WO 01/92340 (2001-12-01), None
Willis-Karp et al. Science, vol. 282, pp. 2258-2261, Dec. 18, 1998.
Hultgren O et al. “Staphylococcus aureus-induced septic arthritis and septic death is decreased in IL-4 -efficient mice: role of IL-4 as promoter for bacterial growth.”,J. Immunol 1998:160(10):5082-5087, May 1998.
Holt et al. “Domain antibodies: proteins for therapy,”Trends in Biotechnology, 21(11):484-490, Nov. 2003.
Zurawski S. et al., “The primary binding subunit of the human interleukin-4 receptor is also a component of the interleukin-13 receptor,”J. Biol Chem270(23):13869-13878, Jun. 9, 1995.
Database EPOP: Accession No. AX365126.1, Feb. 15, 2002.
Related International Search Report for PCT/US01/17094.
Hamud Fozia
Immunex Corporation
Machin Nathan A.
O'Hara Eileen
LandOfFree
Methods and compositions relating to anti-interleukin-4... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions relating to anti-interleukin-4..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions relating to anti-interleukin-4... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3804071